Table 2 Subgroup analysis for the effect of statin therapy on cardiovascular disease

Mean Age

> = 60

14,27-29,31-33

853/7119

1211/7223

0.72 [0.65, 0.79]

<0.001

21.2%

0.27

<60

23-25

1614/8856

2042/8925

0.80 [0.75, 0.84]

<0.001

0%

0.50

Cardiovascular History

Yes

28-29,31,34

498/2417

712/2489

0.72 [0.65, 0.80]

<0.001

0%

0.49

No

14,25-26, 32

404/6842

544/6998

0.73 [0.60, 0.88]

0.001

27.6%

0.25

Diabetes

Yes

27-28,34

173/1334

260/1424

0.74 [0.63, 0.88]

<0.001

0%

0.94

No

25,27-28,32-34

329/3123

484/3129

0.68 [0.59, 0.79]

<0.001

10%

0.35

Baseline GFR

> = 60

23,26,28

1914/13046

2481/13280

0.77 [0.71, 0.83]

<0.001

21.9%

0.28

<60

25,29, 32-33

128/2116

203/2127

0.62 [0.47, 0.83]

0.001

29.4%

0.24

Baseline Creatinine

> = 1.5

25,29

80/333

111/339

0.71 [0.45, 1.12]

0.139

11.6%

0.29

<1.5

23,24,28,31-32

1869/10241

2430/10367

0.73 [0.63, 0.84]

<0.001

48.0%

0.10

Baseline Total Cholesterol

> = 5.0

23,28

1816/9513

2337/9527

0.77 [0.70, 0.84]

<0.001

35.6%

0.21

<5.0

24-25,29,31-34

344/3543

509/3585

0.69 [0.60, 0.80]

<0.001

18.1%

0.29

Baseline LDL Cholesterol

> = 3.0

23-25,27-29, 31-32

2131/11220

2809/11389

0.74 [0.70, 0.81]

P < 0.001

29.0%

0.20

<3.0

14,30,33

825/6357

1018/6264

0.76 [0.72, 0.81]

P < 0.001

37.7%

0.20

LDL Cholesterol Lowering

> = 30%

14,23,26,28,29,33

2328/18087

3030/18332

0.77 [0.73, 0.82]

P < 0.001

10.4%

0.35

<30%

24,25,32

32/625

52/636

0.76 [0.71, 0.82]

0.087

35.4%

0.21

Follow Up

> = 3

14,23-24, 26–29,31-32

2523/17823

3320/18136

0.76 [0.72, 0.81]

P < 0.001

14.4%

0.31

<3

25,33

42/1685

77/1675

0.74 [0.69, 0.80]

0.001

0%

0.51